We are live on ! Find out more
RUBY

Rubius Therapeutics

Delisted

RUBY was delisted on the 6th of March, 2023.

85 hedge funds and large institutions have $462M invested in Rubius Therapeutics in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more capital inflows, than outflows

Capital inflows: $20.5M | Capital outflows: $8.16M

78% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 18

64% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 14

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

12% more funds holding

Funds holding: 76 → 85 (+9)

2.29% more ownership

Funds ownership: 93.72% → 96.01% (+2.3%)

Holders
85
Holders Change
+9
Holders Change %
+11.84%
% of All Funds
1.74%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.08%
New
23
Increased
32
Reduced
18
Closed
14
Calls
$268​K
Puts
–
Net Calls
+$268​K
Net Calls Change
+$267​K

RUBY Hedge Fund Activity: Q2 2020 in Review

85 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics (RUBY) for Q2 2020, worth a combined $462M — up 38% from $335M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new RUBY positions and 14 closed out — a net gain of 9 holders — while 32 added to existing stakes and 18 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $5.22M. The largest seller was Capital World Investors, cutting an estimated $3.81M.

  • 85 institutional investors held Rubius Therapeutics (RUBY) as of Q2 2020, up from 76 in Q1 2020.
  • Funds reported $462M of Rubius Therapeutics stock for Q2 2020, up 38% quarter-over-quarter.
  • 23 funds opened new Rubius Therapeutics positions in Q2 2020 and 14 closed out, a net change of +9 holders.
  • The largest Rubius Therapeutics buyer in Q2 2020 was JP Morgan Chase, an estimated $5.22M added.
  • The largest Rubius Therapeutics seller in Q2 2020 was Capital World Investors, an estimated $3.81M sold.

Based on aggregated 13F filings for Q2 2020.